€48.00: That's What Analysts Think Roche Bobois S.A. (EPA:RBO) Is Worth After Its Latest Results

Shareholders might have noticed that Roche Bobois S.A. (EPA:RBO) filed its half-yearly result this time last week. The early response was not positive, with shares down 7.5% to €44.40 in the past week. Roche Bobois reported in line with analyst predictions, delivering revenues of €204m and statutory earnings per share of €3.10, suggesting the business is executing well and in line with its plan. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

View our latest analysis for Roche Bobois

Following last week's earnings report, Roche Bobois' four analysts are forecasting 2024 revenues to be €420.4m, approximately in line with the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of €432.2m and earnings per share (EPS) of €2.92 in 2024. Overall, while there's been a minor downgrade to revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important following the latest results.

Intriguingly,the analysts have cut their price target 7.2% to €48.00 showing a clear decline in sentiment around Roche Bobois' valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Roche Bobois, with the most bullish analyst valuing it at €55.00 and the most bearish at €39.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Roche Bobois' revenue growth is expected to slow, with the forecast 3.9% annualised growth rate until the end of 2024 being well below the historical 12% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.9% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Roche Bobois.

The Bottom Line

The clear low-light was that the analysts cut their forecast revenue estimates for Roche Bobois next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Roche Bobois' future valuation.

We have estimates for Roche Bobois from its four analysts out to 2026, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 2 warning signs for Roche Bobois you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.